A new core–shell nanoparticle containing the chemotherapeutic drug doxorubicin was formulated via amphiphilic graft copolymer self-assembly using curdlan-graft-poly(ethylene glycol) (curdlan-g-PEG). The graft copolymer was synthesized through the dicyclohexylcarbodiimide ester linkage of carboxylated PEG to the hydroxyl groups of the curdlan backbone. The nanoparticles were 109.9 nm in size and encapsulated doxorubicin in high yield (4%–5% wt/wt). The nanoparticles also controlled the release of doxorubicin over 24 h with a release profile that followed a Fickian diffusion model. The biocompatibility of curdlan-g-PEG was confirmed by hemolysis assay. This is the first nanoparticle formulated using the hydrophobicity of curdlan for concealing the immunomodulatory potential of curdlan within the core.
ZhangHBNishinariKWilliamsMAKFosterTJNortonIT. A molecular description of the gelation mechanism of curdlan. Int J Biol Macromol2002; 30(1): 7–16.
2.
OhnoNFurukawaMMiuraNNAdachiYMotoiMYadomaeT. Antitumor beta-glucan from the cultured fruit body of Agaricus blazei. Biol Pharm Bull2001; 24(7): 820–828.
3.
RicePJAdamsELOzment-SkeltonTGonzalezAJGoldmanMPLockhartBE. Oral delivery and gastrointestinal absorption of soluble glucans stimulate increased resistance to infectious challenge. J Pharmacol Exp Ther2005; 314(3): 1079–1086.
4.
WeiDZhangLYWilliamsDLBrowderW. Glucan stimulates human dermal fibroblast collagen biosynthesis through a nuclear factor-1 dependent mechanism. Wound Repair Regen2002; 10(3): 161–168.
5.
PillemerLBlumLLepowIHRossOAToddEWWardlawAC. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science1954; 120(3112): 279–285.
6.
VetvickaVThorntonBPRossGD. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest1996; 98(1): 50–61.
7.
RossGDVetvickaVYanJXiaYVetvickovaJ. Therapeutic intervention with complement and beta-glucan in cancer. Immunopharmacology1999; 42(1–3): 61–74.
8.
KataokaKMutaTYamazakiSTakeshigeK. Activation of macrophages by linear (1 → 3)-beta-D-glucans – implications for the recognition of fungi by innate immunity. J Biol Chem2002; 277(39): 36825–36831.
9.
LehtovaaraBCGuFX. Pharmacological structural, and drug delivery properties and applications of 1,3-β-glucans. J Agric Food Chem2011; 59(13): 6813–6828.
10.
SonckEStuyvenEGoddeerisBCoxE. The effect of beta-glucans on porcine leukocytes. Vet Immunol Immunopathol2010; 135(3–4): 199–207.
11.
DritzSSShiJKielianTLGoodbandRDNelssenJLTokachMD. Influence of dietary beta-glucan on growth-performance, nonspecific immunity, and resistance to streptococcus-suis infection in weanling pigs. J Anim Sci1995; 73(11): 3341–3350.
12.
EicherSDMcKeeCACarrollJAPajorEA. Supplemental, vitamin C and yeast cell wall beta-glucan as growth enhancers in newborn pigs and as immunomodulators after an endotoxin challenge after weaning. J Anim Sci2006; 84(9): 2352–2360.
13.
EvansSGMorrisonDKanekoYHavlikI. The effect of curdlan sulphate on development in vitro of Plasmodium falciparum. Trans R Soc Trop Med Hyg1998; 92(1): 87–89.
14.
JagodzinskiPPWiaderkiewiczRKurzawskiGKloczewiakMNakashimaHHyjekE. Mechanism of the inhibitory effect of curdlan sulfate on HIV-1 infection in-vitro. Virology1994; 202(2): 735–745.
15.
OsawaZMorotaTHatanakaKAkaikeTMatsuzakiKNakashimaH. Synthesis of sulfated derivatives of curdlan and their anti-HIV activity. Carbohydr Polym1993; 21(4): 283–288.
16.
BorjihanGZhongGYBaigudeHNakashimaHUryuT. Synthesis and anti-HIV activity of 6-amino-6-deoxy-(1 → 3)-beta-D-curdlan sulfate. Polym Adv Technol2003; 14(3–5): 326–329.
17.
UngurenasuCPintealaM. Syntheses and characterization of water-soluble C-60-curdlan sulfates for biological applications. J Polym Sci Pol Chem2007; 45(14): 3124–3128.
18.
NakaoYKonnoATaguchiTTawadaTKasaiHTodaJ. Curdlan – properties and application to foods. J Food Sci1991; 56(3): 769–772.
19.
FunamiTFunamiMTawadaTNakaoY. Decreasing oil uptake of doughnuts during deep-fat frying using curdlan. J Food Sci1999; 64(5): 883–888.
20.
FerreiraDSFariaAFGrossoCRFMercadanteAZ. Encapsulation of blackberry anthocyanins by thermal gelation of curdlan. J Braz Chem Soc2009; 20(10): 1908–1915.
21.
NaKParkKHKimSWBaeYH. Self-assembled hydrogel nanoparticles from curdlan derivatives: characterization, anti-cancer drug release and interaction with a hepatoma cell line (HepG2). J Controlled Release2000; 69(2): 225–236.
22.
SubediRKKangKWChoiH. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci2009; 37(3–4): 508–513.
23.
LiLGaoFTangHBaiYLiRLiX. Self-assembled nanoparticles of cholesterol-conjugated carboxymethyl curdlan as a novel carrier of epirubicin. Nanotechnology2010; 21(26): 265601.
24.
RiessG. Micellization of block copolymers. Progr Polymer Sci2003; 28(7): 1107–1170.
25.
MaedaHWuJSawaTMatsumuraYHoriK. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release2000; 65(1–2): 271–284.
26.
KarinagaRAnadaTMinariJMizuMKoumotoKFukudaJ. Galactose-PEG dual conjugation of beta-(1 → 3)-D-glucan schizophyllan for antisense oligonucleotides delivery to enhance the cellular uptake. Biomaterials2006; 27(8): 1626–1635.
27.
KarinagaRKoumotoKMizuMAnadaTShinkaiSSakuraiK. PEG-appended beta-(1 → 3)-D-glucan schizophyllan to deliver antisense-oligonucleotides with avoiding lysosomal degradation. Biomaterials2005; 26(23): 4866–4873.
28.
OhyaYKurodaHHiraiKOuchiT. Synthesis and cytotoxic activity of conjugates of monomethoxy poly(ethylene-glycol) end-capped with doxorubicin via ester, amide, or Schiff-base bond. J Bioact Compat Polym1995; 10(1): 51–66.
29.
YooHSParkTG. Biodegradable polymeric micelles composed of doxorubicin conjugated PLGA–PEG block copolymer. J Control Release2001; 70(1–2): 63–70.
SaitoHHoffmanASOgawaHI. Delivery of doxorubicin from biodegradable PEG hydrogels having Schiff base linkages. J Bioact Compat Polym2007; 22(6): 589–601.
XiongXYTamKCGanLH. Release kinetics of hydrophobic and hydrophilic model drugs from pluronic F127/poly(lactic acid) nanoparticles. J Control Release2005; 103(1): 73–82.
34.
ChoiYHLiuFKimJSChoiYKParkJSKimSW. Polyethylene glycol-grafted poly-l-lysine as polymeric gene carrier. J Control Release1998; 54(1): 39–48.
35.
KangGDCheonSHSongSC. Controlled release of doxorubicin from thermosensitive poly(organophosphazene) hydrogels. Int J Pharm2006; 319(1–2): 29–36.
36.
SiepmannJPeppasNA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Deliv Rev2001; 48(2–3): 139–157.
37.
MocanuGMihaiDLegrosMPictonLLeCerfD. New polysaccharide-based microparticles crosslinked with siloxane: interactions with biologically active substances. J Bioact Compat Polym2008; 23(1): 82–94.
38.
LeungTCWongCKXieY. Green synthesis of silver nanoparticles using biopolymers, carboxymethylated-curdlan and fucoidan. Mater Chem Phys2010; 121(3): 402–405.
39.
KhandwekarAPPatilDPKhandwekarVShoucheYSSawantSDobleM. TecoflexTM functionalization by curdlan and its effect on protein adsorption and bacterial and tissue cell adhesion. J Mater Sci Mater Med2009; 20(5): 1115–1129.
40.
JoSParkK. Surface modification using silanated poly(ethylene glycol)s. Biomaterials2000; 21(6): 605–616.
41.
KohlerNSunCFichtenholtzAGunnJFangCZhangMQ. Methotrexate-immobilized poly(ethylene glycol) magnetic nanoparticles for MR imaging and drug delivery. Small2006; 2(6): 785–792.
42.
ZhangYKohlerNZhangMQ. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials2002; 23(7): 1553–1561.
43.
FarokhzadOCChengJJTeplyBASherifiIJonSKantoffPW. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA2006; 103(16): 6315–6320.
44.
LuuYKKimKHsiaoBSChuBHadjiargyrouM. Development of a nanostructured DNA delivery scaffold via electrospinning of PLGA and PLA–PEG block copolymers. J Control Release2003; 89(2): 341–353.
